Dr. Dorff on greatest unmet need in metastatic castration-sensitive prostate cancer
December 19th 2022Tanya Dorff, MD, explains how the next frontier in mCSPC will be the ability to select patients for treatment based more on molecular stratification and not only on disease volume or metachronous vs synchronous presentation.
Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
December 13th 2022“One of the things that drives me to be a part of advanced prostate cancer care is that literally every 6 months, we are having major trials read out guideline-based changes in care,” says Jason Hafron, MD.
Insight for practicing clinicians on targeted radionuclide therapies for prostate cancer
December 12th 2022“In terms of both numbers of centers [administering radionuclides] as well as the amount of drug that’s available, [both] are going to increase over the next several months and certainly, year,” says Scott T. Tagawa, MD, MS, FACP.
Dr. Tagawa on pivotal trials supporting use of 177Lu-PSMA-617 in prostate cancer
December 8th 2022177Lu-PSMA-617 is approved for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.